Nuvelo completes enrollment in alfimeprase phase 3 studies

By Lisa Kerner

Charlotte, N.C., Sept. 5 - Nuvelo, Inc. completed patient enrollment in two phase 3 trials of alfimeprase, an enzyme that dissolves blood clots by degrading the protein, fibrin.

The company said it enrolled 300 patients in both its Sonoma-2 trial of 3 mg alfimeprase for the treatment of central venous catheter occlusion and the NAPA-2, of 0.3 mg/kg alfimeprase for the treatment of acute peripheral arterial occlusion (leg attack).

A second phase 3 trial of 3 mg alfimeprase in 800 patients with occluded central venous catheters is ongoing and two additional phase 2 trials of alfimeprase for the treatment of acute ischemic stroke and deep venous thrombosis are planned.

The San Carlos, Calif.-based pharmaceutical company is developing alfimeprase in collaboration with Bayer HealthCare.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.